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Abstract
Background: With multifaceted imaging capabilities, cardiovascular magnetic resonance (CMR) is playing a
progressively increasing role in the management of various cardiac conditions. A global registry that harmonizes
data from international centers, with participation policies that aim to be open and inclusive of all CMR programs,
can support future evidence-based growth in CMR.
Methods: The Global CMR Registry (GCMR) was established in 2013 under the auspices of the Society for
Cardiovascular Magnetic Resonance (SCMR). The GCMR team has developed a web-based data infrastructure, data
use policy and participation agreement, data-harmonizing methods, and site-training tools based on results from an
international survey of CMR programs.
Results: At present, 17 CMR programs have established a legal agreement to participate in GCMR, amongst them
10 have contributed CMR data, totaling 62,456 studies. There is currently a predominance of CMR centers with
more than 10 years of experience (65%), and the majority are located in the United States (63%). The most
common clinical indications for CMR have included assessment of cardiomyopathy (21%), myocardial viability (16%),
stress CMR perfusion for chest pain syndromes (16%), and evaluation of etiology of arrhythmias or planning of
electrophysiological studies (15%) with assessment of cardiomyopathy representing the most rapidly growing
indication in the past decade. Most CMR studies involved the use of gadolinium-based contrast media (95%).
Conclusions: We present the goals, mission and vision, infrastructure, preliminary results, and challenges of the
GCMR.
Trial registration: Identification number on ClinicalTrials.gov: NCT02806193. Registered 17 June 2016.
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Background
Over the past decade, cardiovascular magnetic resonance
(CMR) has become a key clinical imaging method for
the evaluation of a wide range of heart and vascular dis-
eases. A registry that fosters multicenter participation
will gather evidence of the real-world diagnostic and
therapeutic impact of CMR on patient care, key issues
guiding future technical development, clinical adapta-
tion, regulatory approval, and financial reimbursement.
The European CMR Registry (EuroCMR) with now over
37,000 patients from 57 European centers has demon-
strated CMR’s impact on clinical diagnosis and manage-
ment in Europe [1, 2]. Given the worldwide clinical
adaptation of CMR in the past decade, the Society for
Cardiovascular Magnetic Resonance (SCMR) in 2013
initiated and has since continued to support the devel-
opment of a global registry. The Global CMR Registry
(GCMR) aims to promote evidence-based adoption of
CMR into patient management by facilitating standard-
ized data collection across many centers of diverse
patient demographics and clinical outcomes, qualitative
and quantitative CMR results, determination of the
downstream impact of CMR on diagnostic and thera-
peutic thinking, and its cost-effectiveness.
Methods/design
Mission and vision of GCMR
The overarching vision of GCMR is to provide a central,
representative collective platform to demonstrate the
impact of clinical CMR applications on patient care and
how CMR’s diagnostic and prognostic value impact pa-
tient management. Participation in GCMR is open to all
CMR programs worldwide. Programs are encouraged to
participate irrespective of their countries or regions,
practice setting (e.g. academic, community), stage of
CMR program development, or pre-existing CMR vol-
ume. It is the opinion of the GCMR steering committee
that “real-world” data from clinical CMR practices will
foster accurate cost-utility and cost-effectiveness ana-
lyses, with the vision of quantifying CMR’s impact over
time towards improving the life expectancy and quality
of life for patients with cardiovascular diseases. To suc-
ceed, GCMR has been set up as a platform that is inclu-
sive and adaptable to promote collaboration amongst as
many programs as possible, with data collection proce-
dures that minimize the additional work burden of par-
ticipating sites.
GCMR organization
GCMR development is closely supported and supervised
by the SCMR leadership. The organization of the GCMR
includes a) the Chief Executive Officer and the Executive
Committee of the SCMR, including its President, Vice
President, Secretary-Treasurer, Vice Secretary-Treasurer,
and Immediate Past-President, b) the GCMR committee,
and c) a data management team. SCMR has not only pro-
vided the seed funding and support for the development
of the infrastructure of GCMR website, but is directly co-
ordinating the legal and contractual correspondence with
all participating sites. Detailed and up-to-date information
on GCMR, including its goals, vision and mission, leader-
ship, roadmap of future GCMR development, data policy
standards, template contractual agreements, current par-
ticipating sites and investigators, lists of variables, and a
sample Internal Review Board (IRB) protocol, can be
found at the website http://gcmr-scmr.org.
The GCMR steering committee serves directly under
the auspices of SCMR over a renewable 3-year term,
overseeing all aspects of the development of this
global registry. Additional file 1: Table S1 lists the
current members of the GCMR steering committee
[see Additional file 1: Table S1]. It consists of an inter-
national panel appointed by the SCMR from diverse disci-
plines and geographic regions. The steering committee
serves to guide the development of registry policies and
infrastructure, and utilization of the registry data. In
addition, the steering committee makes executive deci-
sions regarding research proposals and projects based on
the scientific merits of the proposals. The data manage-
ment team consists of clinician scientists, experts in infor-
mation technology and webpage development, and a
project manager. These members are responsible for ad-
vancing the GCMR database infrastructure, enrollment
and training of participating sites, and harmonization of
de-identified data.
Roadmap of GCMR development
The GCMR project plan calls for three distinct but over-
lapping phases. Figure 1 illustrates the projected devel-
opment of GCMR over these phases. During the first
phase, a web-based secure database infrastructure for
creating an international network was developed and ex-
panded. In the second phase, the current stage of devel-
opment, the GCMR team focuses on the enrollment and
training of CMR programs from diverse geographic re-
gions. During this phase, the GCMR team first assesses
the data collection methods and technical challenges of
any given site, and then proposes a data contribution
plan specific for the site. A data use policy document, a
legal agreement between SCMR and the participating
site, and an IRB protocol template have been prepared
by a GCMR core team and are sent to each participating
site to ensure a clear understanding of the goals and ob-
ligations of both parties. The third phase will commence
when research concepts designed to utilize GCMR data
are submitted to the steering committee for evaluation
and approval. If the results of a research project are re-
ported in a journal, sites that contributed significant
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amount of data to the project will be granted author-
ships. Although GCMR is currently in the second phase,
aspects of the first phase (e.g. recruitment, training, web-
site development) are ongoing and iterative.
Phase I: infrastructure development
Key data variables and the GCMR website
A vital element in multicenter collaboration in GCMR
lies in standardizing a list of key data variables that can
be collected during clinical workflow of CMR imaging,
balancing between data comprehensiveness and onerous-
ness. A registry website of GCMR [www.gcmr-scmr.org]
has been designed and implemented. The list of the
current key GCMR variables (required and recom-
mended) at the time of this writing can be found in the
[see Additional file 2: Table S2] and at https://gcmr.
bwh.harvard.edu/data/wiki_pages/10/database_variables.
htm. The GCMR website also provides documents includ-
ing the latest list of participating GCMR programs
and case volume status, downloadable site-participation
legal agreements, GCMR data policies, IRB protocol
templates, and the GCMR vision and mission statements.
The GCMR website supports uploading of formatted de-
identified data fields spanning patient demographics, car-
diac histories, CMR metrics including cardiac function,
tissue characterization, pulse sequence descriptions and
imaging protocols. In addition, it allows uploading and
viewing of DICOM image files. The GCMR website
performs automated anonymization of all protected
health information in the DICOM headers during the
uploading process. The GCMR registry has been reg-
istered on ClinicalTrials.gov (ID: NCT02806193).
GCMR Web based tools to facilitate site participation
From the inception of GCMR development, it was con-
sidered crucial to incorporate the process of data collec-
tion into the clinical workflow to reduce or minimize
the time burden placed on the participating sites. In
addition, the future success of the GCMR depends on an
effective method of merging standardized data across all
participating sites. To fulfill both requirements, the GCMR
endorsed a non-profit web database (CMR Cooperative,
https://cmrcoop.partners.org/) for collecting standardized
PHI-free data at participating sites. Multi-level access privi-
leges are administered at the individual sites’ level, which
allows sites to use this web tool for local reporting and re-
search purposes. Key features of CMR Cooperative in-
clude rapid collection of the most critical data variables
for accurate and effective clinical reporting and contribu-
tion to GCMR. However, CMR Cooperative provides a
host of other functions that a site can utilize in performing
its own clinical or research activities, as follows:
 Data collection in patient demographics and study
protocols relevant in major common CMR and
CCT indications
 Data collection in cardiac events and diagnostic or
therapeutic impact of imaging
 Data collection of concurrent cardiac imaging tests
including storage of ECG records
 Data collection of segmental maps for perfusion,
wall motion, late gadolinium enhancement, T1 and
T2 mapping imaging
 Report generation for both CMR and cardiac
computed tomography (CCT) studies
 An option of rapid report generation by a single-page
data entry
 Site-specific administration of users’ privileges and
account access
 Site-specific encryption key of all PHI, generated
independently by each site
 Site-specific customization of reporting formats and
other functions
 Site-specific unlimited downloading of its own latest
datasets
 A scheduling module for tracking of CMR or CCT
studies and corresponding study staff
 Criteria-based constructible search of a site’s own data
 Batch uploading of selected data variables
 Training manuals, videos, and recorded webinars
Fig. 1 Phases of GCMR development in establishing database infrastructures, site recruitment, and assessment of clinical impact
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The Supplemental section [See Additional file 3: Figure
S1, Additional file 4: Figure S2, Additional file 5: Figure
S3, Additional file 6: Figure S4, Additional file 7: Figure
S5, Additional file 8: Figure S6, Additional file 9: Figure
S7, Additional file 10: Figure S8] illustrates a series of the
selected webpages of CMR Cooperative. Participating sites
can provide efficient clinical reporting as well as concur-
rently fulfilling the GCMR data requirement.
Other than using the GCMR-affiliated web database,
sites may also contribute to GCMR by providing data that
conform to the data formats specified by GCMR, per the
key data variable list as illustrated [See Additional file 4:
Figure S2] or in weblink https://gcmr.bwh.harvard.edu/
data/wiki_pages/10/database_variables.htm. GCMR data
management team also has harmonized data submit-
ted by selected sites into the GCMR database and will
continue to do so.
Data security
All data contributed by sites are collected in accordance
with HIPAA or other privacy legislation in place in the
countries of the respective contributing sites. Data
collected and stored in GCMR does not contain any pro-
tected health information (PHI). A full description of
PHI and guidance regarding methods for de-identifica-
tion of PHI in accordance with the Privacy Rule of the
Health Insurance Portability and Accountability Act
(HIPAA) of 1996 can be found at http://www.hhs.gov/
hipaa/for-professionals/privacy/special-topics/de-identifi-
cation/. CMR Cooperative encrypts all PHI in transit (all
access is provided exclusively via a secure HTTPS connec-
tion) and during data storage. In addition, a client-side en-
cryption method [3] has been made available to sites to
create and manage their own private encryption keys. For
sites that utilize their own institution-developed software
in data collection, all PHI were removed before data were
submitted to GCMR for processing and storage in the re-
pository. All GCMR data servers utilize open-source tech-
nologies: Ubuntu long term support (LTS) distribution of
Linux, MySQL database, and Nginx web server. The web
applications are built using the Ruby on Rails (RoR) appli-
cation framework. The network connection is secured
(128-bit encryption, TSL 1.2) and authenticated using
AES_128_GCM and DHE_RSA as the key exchange
mechanisms.
Phase II: site proliferation
Institutional review and site initiation
While IRB approval may not be required for retrospect-
ive collection of de-identified data, the GCMR strongly
recommends local IRB approval and all participating
sites are expected to consult their local IRB prior to sub-
mitting any data. GCMR provides prospective sites with
initiation packages including a password-secure account
to its web database and associated training materials
(instructional manual and video files), IRB application
samples, and a list of key GCMR variables including their
variable formats. In addition, the central GCMR team of-
fers a series of webinars for site training purposes.
Legal agreement between each participating site and the
SCMR
Each participating site is required to have the official
agreement issued by the SCMR signed by its institu-
tional signatory or designated representative. Approval
of the terms of the agreement by a legal signatory at the
site is considered a prerequisite for GCMR participation.
Policy towards authorships of manuscripts and funding
support
Data use policy A data use policy document has been
distributed to all participating sites and researchers who
are interested in applying for access to de-identified
datasets. It is also available at https://gcmr.bwh.harvard.
edu/about/research_goals. This policy document was
prepared by the GCMR steering committee and ap-
proved by the executive committee of the SCMR. It
serves as a governing guideline for GCMR’s policies in
the areas of publication and participating sites’ rights
and responsibilities to accessing GCMR’s database, and
also describes the decision process used for the approval
of sub-studies. Since GCMR is established under the
auspices of the SCMR, any aspect of the data use policy
of the GCMR must conform to the existing SCMR
policies and bylaws. All researchers, regardless of whether
his/her site has contributed data to GCMR, are en-
couraged to propose research projects that make use
of de-identified GCMR data. Such requests for either
sub-studies aiming at publications or grant proposals
are to be made in writing in the form of a 1–2 page
“request for sub-study” proposal, which will be evalu-
ated by the GCMR steering committee. This evalu-
ation will be based primarily on the level of scientific
merit and the expected clinical impact of the study aims
of the proposal. If approved, data access will be granted to
the researchers for a specific mutually-agreed period de-
termined primarily on the magnitude of the work in-
volved, and only for the purposes of the grant proposal or
sub-study. At the time of the sub-study submission, a
publication plan is also required, detailing hypotheses,
authorship, intellectual property created and timelines.
Recommendations from the International Committee of
Medical Journal Editors’ (ICMJE) regarding authorship
and non-authorship will be followed to the fullest extent
possible. If journals allow, the GCMR participants should
be listed following the authors using the phrase “on behalf
of the GCMR contributors” (www.icmje.org).
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Phase III: clinical impact, outcomes and costs
Research and quality control
The ultimate goals of GCMR are to determine the real-
world value of CMR in disease diagnosis and manage-
ment, and the impact of CMR on healthcare costs. Phase
III will consist of the development and implementation
of prospective projects designed to fulfill these goals.
Participating programs will have the opportunity to sub-
mit research proposals to the steering committee for
consideration. The steering committee will review the
proposals and recommend those that meet criteria for
scientific merit, clinical impact, novelty, and relevance to
the goals of GCMR. Sites that contribute an adequate vol-
ume of data used for the research and data analysis will be
considered for co-authorship in affiliated publications. Po-
tential prospective projects include: assessment of the clin-
ical impact of stress CMR perfusion imaging in patients
with chest pain syndromes, an evaluation of the pertinence
of the current appropriate use criteria (AUC); a comparison
of the diagnostic and therapeutic impact of CMR against
echocardiography and routine angiography in patients pre-
senting with heart failure and unclear etiology; and the
safety of gadolinium-based contrast media. Guidelines
for quality control will also be conducted continu-
ously and will allow for the more experienced sites to
help guide the development of newer programs.
Results
Progress of GCMR to-date
To date, phase I has been completed through the cre-
ation of a web-based database for an international net-
work. Features of this database include a) CMR and
cardiac CT capability, b) client-side encryption of all PHI
using a site-defined security key, c) independent admin-
istration of multi-level user access and password control
by each contributing site, d) rapid single-page data entry
of all required key variable fields, e) report-generating
capability to facilitate clinical workflow, and f) inde-
pendent unrestricted access by each site to its own data.
Site proliferation (phase II) and data collection of clinical
impact, outcomes and costs (phase III) are currently
underway. At the writing of this document, 45 centers
were engaged in the enrollment process, amongst
them 17 had signed the participating agreement. The
countries of origin of these 17 programs include
United States (N = 11), United Kingdom (N = 1), China
(N = 1), Brazil (N = 1), South Africa (N = 1), India (N = 1),
and New Zealand (N = 1). Eleven of the 17 sites (65%)
were considered highly experienced with more than
10 years of clinical CMR performance. At present, 10 sites
(9 of them highly experienced) have contributed clinical
data: a total of 62,456 de-identified CMR studies from
variable time periods between 2000 and 2015, have been
collected and merged into the GCMR data registry. Table 1
shows the data contributions from the 10 sites. These
contributing sites include programs from the United
States of America (n = 8), the United Kingdom (n = 1),
and China (n = 1) (Fig. 2).
Demographic data of the current GCMR cohort
Table 2 demonstrates the demographic pattern of the
cohort. The median age of the cohort was 55 years
[range from 15 to 91] with a preponderance of males
(68%). While the median left ventricular volumes (LVEDV
and LVESV) and ejection fraction (LVEF) were within
normal limits, CMR had been performed in patients
with extreme values of LVEDV (50 ml - 560 ml), LVESV
(30 ml – 350 ml), and LVEF (8 –91%).
Most common clinical indications and pattern of growth
of CMR
Figure 3 illustrates the most common indications for
CMR, using the indications listed in the recent appropri-
ate use criteria guideline [4]. The indication for CMR
was provided in 44,486 studies (71%) from 9 of the 10
current contributing sites. Assessment of cardiomyop-
athy, myocardial viability, planning of pulmonary venous
isolation or electrophysiological ablation procedures,
and assessment of chest pain syndromes using stress
perfusion imaging represent the most common indica-
tions for CMR studies currently in the registry. Figure 4
illustrates the average number of CMR studies per pro-
gram by years, stratified by various CMR indications.
From the study data submitted to GCMR, there has
been a progressive growth of clinical volume in the past
decade, with key indications that demonstrated most
growth include planning of electrophysiological ablation
procedures and assessment of cardiomyopathy, which
had almost tripled and quadrupled from 2006 to 2012,
respectively.
Gadolinium-based contrast media
Figure 5 illustrates the use of the various GBCA. GBCA
use and dosing details were available from 53,742 CMR
studies (86%) from 9 of the 10 sites. From this data, it
was observed that the vast majority of studies (98%)
within the GCMR cohort involved the use of a GBCA.
Leading contrast agents used in the cohort studies in-
cluded gadopentetate dimeglumine [Magnevist, Bayer
AG, Leverkusen, Germany] (57%), gadobenate dimeglu-
mine [Multihance, Bracco Imaging, Milan, Italy] (21%)
and gadobutrol [Bayer AG, Leverkusen, Germany]
(15%). All contributing programs followed a weight-
based dosing algorithm, with 0.2 mmol/Kg as the most
common cumulative dose used for each CMR study.
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CMR protocols and agreement with SCMR consensus
guidelines
Table 3 illustrates the frequencies of the most commonly
performed pulse sequences based on data collected by
sites. Data regarding CMR pulse sequence was available
from 46,426 CMR studies (74%) from 8 sites. Nearly all
(95%) of CMR studies in the current cohort used cine
steady-state free precession imaging. Late gadolinium
enhancement imaging was the second most commonly
utilized method, performed in 73% of studies. Pharmaco-
logical vasodilatation was used in 28%, with adenosine
and regadenoson injections being the most often used.
Interestingly, T1 mapping was reported performed in ap-
proximately 1 out of 4 studies. These patterns regarding
the use of CMR pulse sequences are consistent with the
recommendations of the SCMR [5, 6].
Retrospective vs. Prospective data of the current GCMR
cohort
As shown in Table 1, out of the 10 sites that had con-
tributed data, 5 centers directly entered data using the
GCMR endorsed database (CMR Cooperative) prospect-
ively whereas the other 5 centers provided retrospective
data collected using their own institutional database.
The GCMR endorsed database (CMR Cooperative) has
been established since September of 2008. The centers
that use the GCMR endorsed database contributed
23,781 of the 62,456 (38%) CMR studies. All sites that
are currently contributing data have agreed to collecting
all key variables and to conform to the format of the var-
iables defined by the GCMR. This condition is also a
condition for all future sites to participate in GCMR. It
appears that having 2 separate methods of contributing
Table 1 Current CMR volume in GCMR
CMR Program Database Used Years of CMR
Contributed
Number of CMR Cases
Contributed
Conformed to GCMR data
format since year
Brigham and Women’s Hospital GCMR-endorsed 2001–2015 10,537 2001
Central Utah Clinic Institution developed 2002–2012 9,237 2016
National Institutes of Health GCMR-endorsed 2001–2016 7,324 2015
Ohio State University Institution developed 2004–2011 11,267 2016
Oklahoma Heart Institute Institution developed 1999–2013 7,316 2016
University of Oxford Institution developed 2002–2015 8,714 2016
St. Francis Hospital Institution developed 2012–2015 2,141 2015
University of South Florida GCMR-endorsed 2009–2015 1,886 2009
West China Hospital GCMR-endorsed 2011–2015 3,060 2011
Wilford Hall Medical Center GCMR-endorsed 2007–2015 974 2007
Total 62,456
Fig. 2 Security structures of GCMR web database
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data to GCMR, by either directly using GCMR endorsed
database or adherence to the data field formats, has en-
couraged more sites to participate by allowing sites to
preserve their clinical workflow. It is anticipated that
with the current efforts in standardizing data variables
and variable formats, consistency of the pooled data will
continue to increase.
Data completeness
Completeness of data in the current GCMR pooled data-
base collected from the 10 contributing sites is shown in
Table 1. In the whole cohort, data fields that contained
the highest percentage of reported missing data included
right ventricular measurements (62%), left ventricular
myocardial mass (34%), and presence or absence of late
gadolinium enhancement (37%). Reasons for missing
data in right ventricular measurements and left ventricu-
lar myocardial mass included technical problem in
image acquisition, limited scanning per CMR indication,
and routine protocoling per site. Reasons for omitted
reporting of late gadolinium enhancement included the
same reasons but in addition also the lack of a clinical
indication for, or even the presence of a contraindication
to gadolinium-based contrast agents (GBCA) adminis-
tration. Across all data fields examined, percentages
of missing data were lower amongst the 5 sites that
used the GCMR endorsed database.
Concerted data collection with CMR software vendors
Several CMR software vendors, including Medis Cardio-
vascular Imaging (Leiden, The Netherlands), Circle
Cardiovascular Imaging (Calgary, Alberta), and Heart
Imaging Technologies (Durham, North Carolina) have
agreed to collaborate with GCMR by either aligning
existing data fields or introducing key GCMR data vari-
ables into their software in future releases. It is antici-
pated this will allow additional sites to easily contribute
data to GCMR via automated merging of datasets.
Discussion
The current project represents the first registry with the
goal of integrating data from CMR programs globally,
independent of clinical practice setting and level of ex-
perience of the participating program. The GCMR has
developed a HIPAA-compatible, nonprofit, web-based
database structure to allow integrated data collection
across CMR centers around the globe. Depending on the
clinical or research needs of a given site, PHI is either
removed or encrypted and stored in regional servers.
Analytical and reporting components of our database
are designed to meet the standards of current practice
guidelines supported by the SCMR [5, 6]. This infra-
structure allows data entry as a part of the clinical work-
flow with the goals of reducing the burden of redundant
or onerous data entry. Given the complexity of CMR
technology, multifaceted pulse sequence descriptions,
and the wide range of clinical questions that CMR as-
sesses, it is our opinion that this registry infrastructure
will pave the path towards the growth of an integrated
and a consistent body of evidence reflecting real-world
data on CMR utilization and adoption. GCMR is the
first of its kind to bring world-wide CMR practice pat-
terns and clinical associations together in one unified
database for purpose of evaluating the diagnostic impact
and therapeutic guidance relevant to patient care.
While large-scale randomized prospective clinical tri-
als will continue to provide the most robust evidence in
Table 2 Demographic data of the current GCMR cohort
Characteristics of cases in GCMR
Patient characteristics Percentage of missing data
Whole cohort,
N = 62,456
GCMR endorsed
database,
N = 23,781
Age (years), median
(Q1, Q3)
55 (40, 68) 3% 0.001%
Female sex, % 31.6 3% 0.0004%
Height (m), median
(Q1, Q3)
1.7 (1.6, 1.8) 14% 2%
Weight (kg), median
(Q1, Q3)
79.5 (66.0, 93.8) 14% 2%
BSA (m2), median
(Q1, Q3)
1.9 (1.6, 2.1) 14% 2%
Cardiac Function, median (Q1, Q3)
LVEDV (ml) 145.0
(115.0, 182.0)
15% 10%
LVESV (ml) 57.7 (41.0, 83.0) 15% 10%
LVEF, calculated
or estimated (%)
59.6 (51.2, 66.0) 10% 10%
LV Mass (gram) 118.0
(91.0, 154.0)
34% 19%
RVEDV (ml) 131.0
(96.0, 168.0)
62% 17%
RVESV (ml) 54.6 (35.0, 77.1) 62% 17%
LVEDVI (ml/m2) 79.6 (63.2, 110.0) 17% 11%
LVESVI (ml/m2) 33.2 (37.0, 23.5) 17% 11%
Cardiac History, %
History of MI 13.6 15% 6%
History of PCI 12.7 16% 6%
History of CABG 5.5 16% 6%
History of HTN 41.8 15% 6%
History of DM 15.0 15% 6%
Rest wall motion
abnormality, %
26.4 19% 9%
Abnormal late
gadolinium
enhancement, %
12.5 37% 9%
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guiding patient care, they can introduce selection bias,
are costly, and in many clinical situations are impractical
to conduct. Retrospective and prospective patient regis-
tries collecting real-world evidence can provide an alter-
native, complementary, and practical assessment for
those conditions that are difficult to study in random-
ized trial settings. GCMR was designed to store a com-
prehensive range of data, which will enable researchers
to evaluate various clinical outcome variables such as
hospitalization, death, heart failure, arrhythmia and inter-
vention as well as their relationship with commonly
assessed clinical parameters, including cardiac function,
chamber quantification, and myocardial perfusion. In con-
trast with clinical trials, which demand controlled condi-
tions and tasks that are not usually reflective of daily
clinical practice, patient registries provide a venue for col-
lecting and storing data that correspond to parameters
that are often routinely recorded. As such, patient
registries are advantageous in that they are more amen-
able to mass-scale observational research and less prone
to increasing the burden on participating CMR centers.
The EuroCMR Registry has prospectively enrolled over
37,000 patients from 57 centers in 15 European coun-
tries. Over the past decade, the EuroCMR Registry has
led to new knowledge that is important to the clinical
adoption of CMR: management changes were observed
in approximately two-thirds of patients following a CMR
scan [1]; the safety profile of pharmacological vasodilata-
tion for stress CMR was demonstrated, as was the safety
of GBCM at dosage appropriate for CMR [7]; and the
prognostic implications of late gadolinium enhancement
in hypertrophic cardiomyopathy patients [8] was investi-
gated. More recently, a health economics study used the
EuroCMR Registry data to demonstrate that a strategy
of CMR as gatekeeper for invasive coronary angiograms
can save costs when compared with a direct invasive
Fig. 3 Most common CMR indications by ‘Appropriate Use Criteria’ categories
Fig. 4 Growth of CMR indications in the GCMR cohort, 2001–2012. Average number of CMR studies across indications by year
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strategy including fractional flow reserve measurements
in patients with low to intermediate pre-test probability
for obstructive coronary artery disease [9]. GCMR aims
to learn from the successes of the EuroCMR Registry.
While currently substantially less-developed than the
EuroCMR Registry, GCMR is expected to continue to
grow in CMR case volumes, geographic distribution
and number of participating sites, and diversity of
sites’ CMR experience.
Challenges ahead
The GCMR faces several key challenges. First, retro-
spective data has a high proportion of missing entries as
a portion of the data were collected prior to the estab-
lishment of a data variable list and variable formats.
However, we observed substantially higher adherence
rates of data entry amongst sites that had adopted the
use of the GCMR endorsed database. Nonetheless, given
that key variables such as major demographic factors,
CMR indications, and contrast use are available in most
of the sites, we believe that the current retrospective
cohort represents a unique resource to assess CMR
utilization patterns in the past and inform directions for
growth in the future. Going forward, it is expected that
participating sites will converge in their data collection
methods prospectively, regardless of methods of data
collection, and the quality of the data collected will im-
prove. Second, the use of native languages in CMR
reporting from various geographic regions poses an ex-
pected challenge as GCMR expands. An effort from an
international panel of CMR experts is currently under-
way in translating the web based data structures into
various languages.
Conclusion
It is believed that the advantages of GCMR will be realized
through its visions - becoming a universally representative
CMR registry globally backed by the SCMR and a sup-
portive and unifying data policy, user-friendly web data
structures that are conducive to clinical workflow, and a
Fig. 5 Distribution of the brands of contrast media used in GCMR CMR studies
Table 3 Most common pulse sequence descriptions performed
Pulse sequence Percentage (%)
Cine SSFP 92
T2W FSE 33
T2 Map 8
T1 Mapping 26
Double inversion Fast Spin Echo 16
Phase Contrast Imaging 18
T2 Star 10
Tagging 8
Coronary MRA using navigator 5
Late gadolinium enhancement 73
Rest Perfusion 64
Adenosine Vasodilating Perfusion 16
Dobutamine Stress Studies 2
Regadenoson Vasodilating Perfusion 8
Dipyridamole Vasodilating Perfusion 4
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goal of making a positive impact on patient care.
GCMR provides the chance to acquire real-world,
multi-dimensional evidence that can be used in many
ways. Examples include a) to compare the clinical effect-
iveness of CMR with other imaging modalities, b) to con-
duct quality control of CMR images and data, which can
be used to narrow the performance gap between nascent
and experienced programs; c) to determine the cost-
effectiveness of CMR when applied in important and com-
mon clinical scenarios; d) to study the impact on patient
outcomes as compared to other imaging modalities. As an
international registry, GCMR will offer opportunities to
study variations across geographic regions, types of CMR
center and CMR expertise in use of CMR protocols,
performance, and clinical applications. Ultimately, the pri-
mary philosophy and goal of SCMR’s GCMR is to improve
life expectancy and quality of life of patients with cardio-
vascular diseases.
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